Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 42/100

Q3 2020 Affimed NV Earnings Call Transcript

Nov 10, 2020 / 01:30PM GMT
Release Date Price: $33
Operator

Good day, everyone, and thank you for standing by, and welcome to Affimed's Third Quarter 2020 Financial Results and Corporate Update Conference Call. As a reminder, today's conference call is being recorded.

I would now like to introduce to -- your host for today's conference call, sir Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, operator. I'd like to welcome and thank you all for joining us today for Affimed's Third Quarter 2020 Financial Results and Operating -- Operational Update Call.

Before we begin, I'd like to remind everyone that the press release issued earlier today related to our earnings call can be found on the Investor Relations section of our website. We have also posted update slides -- updated slides that will be used to guide our discussion today.

On the call today, we have Dr. Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Dr. Wolfgang Fischer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot